🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
05/10/2018 63,50 65,20 62,50 64,20 +0,47% 4,25% 174.960
04/10/2018 65,10 65,20 63,80 63,90 -1,24% 2,15% 147.025
03/10/2018 64,80 65,30 64,40 64,70 -0,31% 1,39% 93.087
02/10/2018 65,20 66,20 64,60 64,90 -1,67% 2,45% 180.277
01/10/2018 66,60 68,70 65,70 66,00 +1,38% 4,50% 181.496
28/09/2018 65,30 66,70 64,80 65,10 +0,62% 2,91% 111.743
27/09/2018 64,80 65,30 63,60 64,70 -2,71% 2,62% 166.094
26/09/2018 68,20 69,20 66,30 66,50 -1,48% 4,25% 140.436
25/09/2018 67,50 70,30 66,90 67,50 +2,90% 5,04% 227.208
24/09/2018 66,20 67,00 64,60 65,60 -1,94% 3,63% 178.640
21/09/2018 70,00 70,00 66,50 66,90 -2,34% 5,00% 280.807
20/09/2018 70,20 71,80 67,80 68,50 -4,60% 5,70% 603.656
19/09/2018 78,00 82,40 71,70 71,80 -11,79% 13,72% 731.491
18/09/2018 81,40 81,40 81,40 81,40 +0,00% 0,00% 0
17/09/2018 88,00 94,80 79,00 81,40 -0,49% 17,95% 529.409
14/09/2018 79,00 82,70 78,60 81,80 +5,96% 5,19% 123.946
13/09/2018 77,50 78,10 76,30 77,20 +0,52% 2,32% 48.028
12/09/2018 77,00 78,00 76,50 76,80 +1,05% 1,95% 45.188
11/09/2018 75,90 76,20 74,70 76,00 +1,33% 1,98% 44.296
10/09/2018 78,20 78,20 75,00 75,00 -3,47% 4,09% 29.715
07/09/2018 77,90 78,60 76,80 77,70 -1,40% 2,31% 54.521
06/09/2018 81,00 81,40 78,60 78,80 -2,60% 3,46% 31.086
05/09/2018 82,40 82,60 80,80 80,90 -1,34% 2,18% 44.700
04/09/2018 81,80 83,00 80,50 82,00 +1,23% 3,06% 46.270
03/09/2018 80,30 82,20 80,30 81,00 +1,00% 2,37% 19.436
31/08/2018 79,90 80,80 79,40 80,20 +0,88% 1,75% 21.298
30/08/2018 78,70 79,80 78,40 79,50 +0,13% 1,78% 19.648
29/08/2018 80,00 80,00 79,10 79,40 +0,13% 1,13% 19.416
28/08/2018 79,00 80,20 78,80 79,30 -0,25% 1,77% 21.313
27/08/2018 79,20 79,90 79,00 79,50 +0,00% 1,14% 16.187